Results 31 to 40 of about 212,526 (280)

Bruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema [PDF]

JAAD Case Reports
Shannon Meledathu, BS, Paul Chu, MD, Tatyana Feldman, MD, Andre Henri Goy, MD, Rachel Kushner Rosenstein, MD, PhD   +4 more
doaj   +2 more sources

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances

Leukemia, 2020
Bruton’s tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval.
T. Wen, Jin-song Wang, Yuankai Shi, H. Qian, Peng Liu   +4 more
semanticscholar   +1 more source

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions

Allergy. European Journal of Allergy and Clinical Immunology, 2022
Bruton's tyrosine kinase (BTK), a member of the Tec kinase family, is critically involved in a range of immunological pathways. The clinical application of BTK inhibitors for B‐cell malignancies has proven successful, and there is strong rationale for ...
P. Mendes‐Bastos, A. Brasileiro, P. Kolkhir, Stefan Frischbutter, J. Scheffel, S. Moñino-Romero, M. Maurer   +6 more
semanticscholar   +1 more source

Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Clinical Cancer Research, 2020
Purpose: Mantle-cell lymphoma (MCL) is an incurable mature B-cell neoplasm with high initial response rates followed almost invariably by relapse. Prognosis for patients following relapse is poor, and treatment choices are limited.
Yuqin Song, K. Zhou, D. Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, J. Ji, Wei Xu, Jie Jin, F. Lv, R. Feng, Sujun Gao, Haiyi Guo, Lei Zhou, R. Elstrom, Jane E. Huang, W. Novotny, R. Wei, Jun Zhu   +19 more
semanticscholar   +1 more source

Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures

Frontiers in Immunology, 2021
Clinical development of BTK kinase inhibitors for treating autoimmune diseases has lagged behind development of these drugs for treating cancers, due in part from concerns over the lack of selectivity and associated toxicity profiles of first generation ...
G. Ringheim, M. Wampole, Kinsi Oberoi
semanticscholar   +1 more source

Regulatory phosphorylation of Ikaros by Bruton's tyrosine kinase. [PDF]

PLoS ONE, 2013
Diminished Ikaros function has been implicated in the pathogenesis of acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Therefore, a stringent regulation of Ikaros is of paramount importance for normal lymphocyte ontogeny ...
Hong Ma, Sanjive Qazi, Zahide Ozer, Jian Zhang, Rita Ishkhanian, Fatih M Uckun   +5 more
doaj   +1 more source

Targeting Brutons Tyrosine Kinase in Chronic Lymphocytic Leukemia at the Crossroad between Intrinsic and Extrinsic Pro-survival Signals [PDF]

, 2016
Chemo immunotherapies for chronic lymphocytic leukemia (CLL) showed a positive impact on clinical outcome, but many patients relapsed or become refractory to the available treatments.
Facco, Monica, Frezzato, Federica, Martini, Veronica, Semenzato, Gianpietro, Severin, Filippo, Trentin, Livio, Trimarco, Valentina, Visentin, Andrea   +7 more
core   +1 more source

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis & Rheumatology, 2021
Fenebrutinib (GDC‐0853) is a noncovalent, oral, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of fenebrutinib in systemic lupus erythematosus (SLE) were assessed in this phase II, multicenter,
D. Isenberg, R. Furie, N. S. Jones, P. Guibord, J. Galanter, Chin H Lee, A. Mcgregor, Balazs Toth, J. Rae, O. Hwang, R. Desai, A. Lokku, N. Ramamoorthi, J. Hackney, P. Miranda, V. A. de Souza, J. Jaller-Raad, A. Maura Fernandes, Rodrigo García Salinas, L. Chinn, M. Townsend, A. Morimoto, K. Tuckwell   +22 more
semanticscholar   +1 more source

Safety and Efficacy of Tyrosine Kinase Inhibitors in Immune Thrombocytopenic Purpura: A Systematic Review of Clinical Trials

Journal of Xenobiotics, 2023
Immune thrombocytopenic purpura (ITP) is an acquired antibody or cell-mediated platelet damage or decreased platelet production. Steroids, IV immunoglobulins (IVIG), and Rho-anti-D antibodies are the commonly used initial treatments for ITP.
Muhammad Ashar Ali, Muhammad Yasir Anwar, Wajeeha Aiman, Gurneel Dhanesar, Zainab Omar, Mohammad Hamza, Maha Zafar, Harish Kumar Rengarajan, Michael Maroules   +8 more
doaj   +1 more source

Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML [PDF]

, 2014
Pharmacological targeting of BTK using ibrutinib has recently shown encouraging clinical activity in a range of lymphoid malignancies. Recently we reported that ibrutinib inhibits human acute myeloid leukemia (AML) blast proliferation and leukemic cell ...
Bowles, Kristian M, Lawes, Matthew J, MacEwan, David J, Murray, Megan Y, Rushworth, Stuart A, Shafat, Manar S., Zaitseva, Lyubov   +6 more
core   +2 more sources